Evidence map›Paper›PMID 40269272›Full record

ArticleLeukemia2025

MEK inhibitors are effective in Erdheim-Chester disease regardless of MAPK pathway mutations.

Francesco Pegoraro, Fleur Cohen-Aubart, Matthias Papo, Francesco Catamerò, Jerome Razanamahery, Zahir Amoura, Jean-François Emile, Augusto Vaglio, Julien Haroche

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Francesco PegoraroDepartment of Hematology and Oncology, Meyer Children's Hospital IRCCS, Florence, Italy.ORCID http://orcid.org/0000-0002-4954-5744
Fleur Cohen-AubartSorbonne University, Internal Medicine Department 2, Institut E3M, French Reference Centre for Histiocytosis, Pitié-Salpȇtrière Hospital, CIMI INSERM-UMRS 1135, Assistance Publique-Hôpitaux de Paris, Paris, France.
Matthias PapoSorbonne University, Internal Medicine Department 2, Institut E3M, French Reference Centre for Histiocytosis, Pitié-Salpȇtrière Hospital, CIMI INSERM-UMRS 1135, Assistance Publique-Hôpitaux de Paris, Paris, France.
Francesco CatameròDepartment of Health Sciences, University of Florence, Florence, Italy.ORCID http://orcid.org/0009-0001-5633-9025
Jerome RazanamaheryInternal Medicine and Clinical Immunology Department, Dijon University Hospital, Dijon, France.
Zahir AmouraSorbonne University, Internal Medicine Department 2, Institut E3M, French Reference Centre for Histiocytosis, Pitié-Salpȇtrière Hospital, CIMI INSERM-UMRS 1135, Assistance Publique-Hôpitaux de Paris, Paris, France.
Jean-François EmileEA4340 BECCOH, Versailles SQY University, Pathology Department, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne, France.ORCID http://orcid.org/0000-0002-6073-4466
Augusto VaglioNephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Julien HarocheSorbonne University, Internal Medicine Department 2, Institut E3M, French Reference Centre for Histiocytosis, Pitié-Salpȇtrière Hospital, CIMI INSERM-UMRS 1135, Assistance Publique-Hôpitaux de Paris, Paris, France. julien.haroche@aphp.fr.ORCID http://orcid.org/0009-0003-9794-1316

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40269272
PMCPMC12133560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.